Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05540262 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Edaravone in the Treatment of Optic Neuritis

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 27, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment target: 18 to 50
    • Primary and study completion dates: Dec 31, 2024 to Dec 31, 2025
    • Study title shortened, about 2 words
    v6
  2. 2 versions Re-verified since Feb 21, 2024, no change to tracked fieldsv4-v5
  3. Start date changed from estimate of Sep 15, 2022 to Jan 15, 2022v3
  4. Secondary endpoints revised (2)v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Edaravone has demonstrated a beneficial effect in promoting remyelination and protecting axons in animals with NMOSD. The researchers posit that edaravone may enhance visual outcomes in patients with aquaporin-4 antibody-positive optic neuritis.
Trial Details
NCT Number NCT05540262
Lead Sponsor First Affiliated Hospital of Guangxi Medical University
Conditions
(from sponsor)		 Optic Neuritis
Related terms Optic Neuritis
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov